{"id":7296,"date":"2026-03-20T11:36:10","date_gmt":"2026-03-20T11:36:10","guid":{"rendered":"https:\/\/oncopeptides.com.haus.se\/newsroom\/news\/sofia-heigis-presenterade-och-intervjuades-pa-stockholm-corporate-finance-life-science-dagar20-mars-2026\/"},"modified":"2026-03-20T11:36:10","modified_gmt":"2026-03-20T11:36:10","slug":"sofia-heigis-presenterade-och-intervjuades-pa-stockholm-corporate-finance-life-science-dagar20-mars-2026","status":"publish","type":"news","link":"https:\/\/oncopeptides.com.haus.se\/sv\/nyheter\/sofia-heigis-presenterade-och-intervjuades-pa-stockholm-corporate-finance-life-science-dagar20-mars-2026\/","title":{"rendered":"Sofia Heigis presenterade och intervjuades p\u00e5 Stockholm Corporate Finance Life Science-dagar<br>20 mars 2026"},"content":{"rendered":"<p>Oncopeptides vd Sofia Heigis h\u00f6ll nyligen en presentation p\u00e5 Stockholm Corporate Finance Life Science-dagar.<\/p>\n<p>Under presentationen ber\u00e4ttade Sofia mer om bolaget och dess p\u00e5g\u00e5ende arbete med b\u00e5de kommersialisering i Europa, partnerskap i andra delar av v\u00e4rlden samt utveckling av sin pipeline, d\u00e4ribland den nyligen kommunicerade satsningen p\u00e5 en ny sjukdom, glioblastom.<br \/><a href=\"https:\/\/stockholm-corporate-finance.events.inderes.com\/17e-kapitalmarknadsdagar-life_science-2026-17-mars-oncopeptides?seek=3\" target=\"_blank\" rel=\"noopener\">Se presentationen via denna l\u00e4nk<\/a>.<\/p>\n<p>I samband med deltagandet satte sig Sofia ocks\u00e5 ned tillsammans med Jesper Hagman p\u00e5 Inderes f\u00f6r en intervju, d\u00e4r de bland annat diskuterade Oncopeptides l\u00e4kemedel och marknadspotential, den nyligen genomf\u00f6rda nyemissionen, nya studier och bolagets strategi f\u00f6r tillv\u00e4xt.<\/p>\n<p>Se intervjun nedan eller <a href=\"https:\/\/www.inderes.se\/videos\/intervju-med-oncopeptides-vd-under-scfs-17e-kapitalmarknadsdag-life-science\" target=\"_blank\" rel=\"noopener\">via denna l\u00e4nk<\/a>:<\/p>\n<p><iframe title=\"Intervju med Oncopeptides VD under SCF:s 17:e Kapitalmarknadsdag Life Science\" width=\"800\" height=\"450\" src=\"https:\/\/www.youtube.com\/embed\/wImdJi2IGLQ?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n","protected":false},"featured_media":7295,"template":"","meta":{"_acf_changed":false},"news_categories":[365],"protected-content":[],"class_list":["post-7296","news","type-news","status-publish","has-post-thumbnail","hentry","news_categories-investerare"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/news\/7296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/media\/7295"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/media?parent=7296"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/news_categories?post=7296"},{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/protected-content?post=7296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}